Assessing the efficacy of combined Escitalopram and Buspirone in late life depression accompanied by cognitive impairment:An open label randomised controlled trail
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- To compare the efficacy of combined Escitalopram (10 mg) and Buspirone (30 mg) vs Escitalopram (10 mg) monotherapy in improving cognition among elderly patients with Depression accompanied by cognitive impairment.
研究概览
简要总结
The thesis titled "Assessing the efficacy of combined Escitalopram and Buspirone in late life depression accompanied by cognitive impairment: An open label randomised controlled trial" explores the therapeutic potential of combining Escitalopram, a selective serotonin reuptake inhibitor(SSRI), with Buspirone, an anxiolytic in treating late life depression that is complicated by cognitive impairment. The research investigates whether this combination offers better outcomes in terms of alleviating depressive symptoms and improving cognitive function compared to Escitalopram monotherapy. The findings aim to provide a deeper understanding of how these medications may work synergistically to address the complex interaction between mood disorders and cognitive decline in older adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 65.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- All
入选标准
- •Diagnosed with current Depressive episode according to ICD-11 (Single Episode Depressive Disorder / Recurrent Depressive Disorder).
排除标准
- •Diagnosed with current depressive episode in Bipolar affective disorder according to ICD-11 2)Presence of psychotic symptoms 3)Any contraindication to the use of Escitalopram or Buspirone 4)Any other co-morbid major psychiatric disorder(Except Tobacco dependence) 5)On current treatment for dementia.
结局指标
主要结局
To compare the efficacy of combined Escitalopram (10 mg) and Buspirone (30 mg) vs Escitalopram (10 mg) monotherapy in improving cognition among elderly patients with Depression accompanied by cognitive impairment.
时间窗: Improvement in cognition and depressive symptoms will be measured at baseline, 4 weeks and 8 weeks
次要结局
- 1)To compare the efficacy of combined Escitalopram (10 mg) and Buspirone (30 mg) vs Escitalopram (10 mg) monotherapy in improving the depressive symptoms among elderly patients with Depression.(2)To compare the side-effect profile and drop-out from treatment in the combined Escitalopram and Buspirone group as compared with Escitalopram monotherapy group.)
研究者
Dr Sayan Kumar Ghosh
Aiims, New Delhi